Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 21, 2005; 11(47): 7391-7400
Published online Dec 21, 2005. doi: 10.3748/wjg.v11.i47.7391
Published online Dec 21, 2005. doi: 10.3748/wjg.v11.i47.7391
Table 1 Major etiologies of HCC
| Chronic viral hepatitis B, C, D |
| Toxins (e.g., alcohol, aflatoxins) |
| Hereditary metabolic liver diseases (e.g., hereditary hemochromatosis, |
| α-1-antitrypsin deficiency) |
| Autoimmune hepatitis |
| Overweight, especially in males, and diabetes mellitus; nonalcoholic |
| steatohepatitis (NASH) or nonalcoholic fatty liver disease (NAFLD) |
Table 2 Okuda stages I-III of HCC
| Tumor mass | <50% of liver | ≥50% of liver |
| Ascites | No | Yes |
| Albumin (g/L) | >3 | ≤3 |
| Bilirubin (mg/dL) | <3 | ≥3 |
| Points | 0 | 1 |
| Stage I | 0 points | |
| Stage II | 1-2 points | |
| Stage III | 3-4 points |
Table 3 Drugs evaluated in clinical trials for the treatment of patients with HCC
| 5-Fluorouracil |
| Capecitabine |
| Doxorubicin |
| Epirubicin |
| Etoposide |
| Cisplatin |
| Gemcitabine |
| Mitoxantrone |
| Interferon alpha |
| Megestrol acetate |
| Tamoxifen |
| Octreotide |
| Thalidomide |
| Thymophysin |
| α-1-thymosin |
- Citation: Blum HE. Hepatocellular carcinoma: Therapy and prevention. World J Gastroenterol 2005; 11(47): 7391-7400
- URL: https://www.wjgnet.com/1007-9327/full/v11/i47/7391.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i47.7391
